ATE298577T1 - Präparate auf purinbasis - Google Patents

Präparate auf purinbasis

Info

Publication number: ATE298577T1
Authority: AT; Austria
Prior art keywords: purine; catecholamine; compound; administered; counteracting agent
Prior art date: 1993-11-24

Application number

AT95904103T

Other languages

English (en)

Inventor

Atsuo F Fukunaga

Alex S Fukunaga

Original Assignee

Atsuo F Fukunaga

Alex S Fukunaga

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-11-24

Filing date

1994-11-21

Publication date

2005-07-15

1994-11-21 Application filed by Atsuo F Fukunaga, Alex S Fukunaga filed Critical Atsuo F Fukunaga

2005-07-15 Application granted granted Critical

2005-07-15 Publication of ATE298577T1 publication Critical patent/ATE298577T1/de

Links

238000002360 preparation method Methods 0.000 title 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 9
-1 purine compound Chemical class 0.000 abstract 7
OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 5
239000003795 chemical substances by application Substances 0.000 abstract 4
230000000694 effects Effects 0.000 abstract 4
239000000203 mixture Substances 0.000 abstract 4
239000002126 C01EB10 - Adenosine Substances 0.000 abstract 3
241000124008 Mammalia Species 0.000 abstract 3
229960005305 adenosine Drugs 0.000 abstract 3
150000003943 catecholamines Chemical class 0.000 abstract 3
238000000338 in vitro Methods 0.000 abstract 1
230000001766 physiological effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Obesity (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT95904103T 1993-11-24 1994-11-21 Präparate auf purinbasis ATE298577T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15801293A	1993-11-24	1993-11-24
US08/341,668 US5679650A (en)	1993-11-24	1994-11-17	Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
PCT/US1994/013412 WO1995014478A1 (en)	1993-11-24	1994-11-21	Purine compositions and methods for administration

Publications (1)

Publication Number	Publication Date
ATE298577T1 true ATE298577T1 (de)	2005-07-15

Family

ID=26854668

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95904103T ATE298577T1 (de)	1993-11-24	1994-11-21	Präparate auf purinbasis

Country Status (10)

Country	Link
US (2)	US5679650A (de)
EP (1)	EP0735888B1 (de)
JP (1)	JP3836128B2 (de)
AT (1)	ATE298577T1 (de)
AU (1)	AU688835B2 (de)
CA (1)	CA2175828A1 (de)
DE (1)	DE69434416T2 (de)
DK (1)	DK0735888T3 (de)
ES (1)	ES2244962T3 (de)
WO (1)	WO1995014478A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5679650A (en) *	1993-11-24	1997-10-21	Fukunaga; Atsuo F.	Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US6004945A (en)	1990-05-10	1999-12-21	Fukunaga; Atsuo F.	Use of adenosine compounds to relieve pain
US6180616B1 (en)	1990-05-10	2001-01-30	Atsuo F. Fukunaga	Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
IL121272A (en) *	1997-07-10	2000-06-01	Can Fite Technologies Ltd	Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
CN1221249C (zh)	1998-08-19	2005-10-05	斯凯伊药品加拿大公司	普鲁泊福的可注射水分散体
US6025362A (en) *	1998-08-31	2000-02-15	Fukunaga; Atsuo F.	Uses of xanthine compounds
US20030166605A1 (en) *	1999-04-27	2003-09-04	Edward Leung	Method of minimizing damage to heart tissue during cardiac surgery and cardiac transplantation
EP1326642A2 (de) *	2000-09-29	2003-07-16	Board of Trustees operating Michigan State University	Catecholamin pharmazeutische zusammensetzungen und verfahren
US7842307B2 (en) *	2001-08-06	2010-11-30	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068375A1 (en)	2001-08-06	2003-04-10	Curtis Wright	Pharmaceutical formulation containing gelling agent
US7332182B2 (en)	2001-08-06	2008-02-19	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7157103B2 (en)	2001-08-06	2007-01-02	Euro-Celtique S.A.	Pharmaceutical formulation containing irritant
EP1575548B1 (de)	2002-05-04	2011-03-09	Acorda Therapeutics, Inc.	Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
KR101057082B1 (ko)	2002-11-21	2011-08-16	코와 가부시키가이샤	복막 투석법
GB0228723D0 (en) *	2002-12-09	2003-01-15	Cambridge Biotechnology Ltd	Treatment of pain
GB0305149D0 (en) *	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Compounds for the treatment of pain
GB0305150D0 (en) *	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Use of therapeutic compounds
GB0305153D0 (en) *	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Identification of therapeutic compounds
EP3211084B1 (de)	2003-05-16	2019-03-27	Acorda Therapeutics, Inc.	Proteoglycan-abbauende mutanten zur behandlung des zns
MXPA05012305A (es) *	2003-05-16	2006-04-18	Acorda Therapeutics Inc	Composiciones y metodos para el tratamiento de lesiones del snc.
US7959914B2 (en)	2003-05-16	2011-06-14	Acorda Therapeutics, Inc.	Methods of reducing extravasation of inflammatory cells
WO2004103263A2 (en) *	2003-05-22	2004-12-02	Yeda Research And Development Co. Ltd.	Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
KR20070004792A (ko) *	2004-03-05	2007-01-09	캠브리지 바이오테크놀로지 리미티드	아데노신 수용체 작용제
ES2653568T3 (es)	2004-06-12	2018-02-07	Collegium Pharmaceutical, Inc.	Formulaciones de fármacos para la prevención del abuso
US20060079479A1 (en) *	2004-10-13	2006-04-13	Italo Biaggioni	Methods of inducing vasodilation
JP5189985B2 (ja)	2005-09-26	2013-04-24	アコーダセラピューティクス、インク．	コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
US7811549B2 (en) *	2006-07-05	2010-10-12	Adenobio N.V.	Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
JP2010504359A (ja)	2006-09-20	2010-02-12	ザボードオブリージェンツオブザユニバーシティーオブテキサスシステム	局部麻酔および／または疼痛緩和のための、揮発性麻酔剤を送達するための方法
AU2007307736C1 (en)	2006-10-10	2014-04-10	Acorda Therapeutics, Inc.	Compositions and methods of using chondroitinase ABCI mutants
CA2712731C (en)	2008-01-22	2016-05-03	The Board Of Regents Of The University Of Texas System	Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US20090185973A1 (en) *	2008-01-22	2009-07-23	Adenobio N.V.	Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
US20110262442A1 (en) *	2009-11-06	2011-10-27	Adenios, Inc.	Compositions for treating cns disorders
WO2011066412A1 (en) *	2009-11-24	2011-06-03	University Of Rochester	Enhancing the therapeutic effect of acupuncture with adenosine
US10668060B2 (en)	2009-12-10	2020-06-02	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20130018010A1 (en) *	2010-04-16	2013-01-17	Enzon Pharmaceuticals, Inc.	Polymeric conjugates of adenine nucleoside analogs
WO2012027695A1 (en) *	2010-08-26	2012-03-01	Northeastern University	Methods and compositions for preventing or treating obesity
PL2826467T3 (pl)	2010-12-22	2018-01-31	Purdue Pharma Lp	Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
PH12013501345A1 (en)	2010-12-23	2022-10-24	Purdue Pharma Lp	Tamper resistant solid oral dosage forms
WO2013120078A1 (en) *	2012-02-11	2013-08-15	Academia Sinica	Methods and compositions for treating pain
AU2013201465B2 (en) *	2012-10-24	2016-03-03	Rayner Intraocular Lenses Limited	Stable preservative-free mydriatic and anti-inflammatory solutions for injection
PE20151301A1 (es)	2013-02-05	2015-09-16	Purdue Pharma Lp	Formulaciones farmaceuticas resistentes a la manipulacion indebida
US10751287B2 (en)	2013-03-15	2020-08-25	Purdue Pharma L.P.	Tamper resistant pharmaceutical formulations
BR112015023671A2 (pt) *	2013-03-15	2017-07-18	Galleon Pharmaceuticals Inc	novos compostos para modulação controlada de respiração e método de uso dos mesmos.
TWI705812B (zh)	2014-12-01	2020-10-01	奥默羅斯公司	用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US9737530B1 (en)	2016-06-23	2017-08-22	Collegium Pharmaceutical, Inc.	Process of making stable abuse-deterrent oral formulations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB797237A (en) *	1955-07-26	1958-06-25	Sterling Drug Inc	Composition for reducing period of anesthesia
ZA7464B (en) *	1973-01-16	1974-11-27	J Voorhees	Treatment of proliferating skin diseases with papavine alkaloids
DE3019322A1 (de) *	1980-05-21	1981-12-03	Merck Patent Gmbh, 6100 Darmstadt	Psychopharmakon sowie verwendung von adenosinderivaten
US4673563A (en) *	1980-10-14	1987-06-16	The University Of Virginia Alumni Patents Foundation	Adenosine in the treatment of supraventricular tachycardia
US4514405A (en) *	1981-09-17	1985-04-30	Merck Patent Gesellschaft Mit Beschrankter Haftung	Use of adenosine derivatives as anticonvulsants
US5049372A (en) *	1982-07-13	1991-09-17	Eliezer Rapaport	Anticancer activities in a host by increasing blood and plasma adenosine 5'-triphosphate (ATP) levels
US4880918A (en) *	1982-07-13	1989-11-14	Eliezer Rapaport	Arrest and killing of tumor cells by adenosine 5-diphosphate and adenosine-5-triphosphate
US4605644A (en) *	1985-02-07	1986-08-12	Regents Of The University Of Minnesota	Method for stimulating recovery from ischemia employing ribose and adenine
FR2577422B1 (fr) *	1985-02-14	1988-10-28	Roussel Uclaf	Association renfermant a titre de principes actifs, un analgesique central et l'adenine ou l'adenosine ou l'un des analogues de l'adenosine
US5104859A (en) *	1985-09-24	1992-04-14	Solimedco Aktiebolag	Continuous administration of adenosine to reduce pulmonary vascular resistance
US4693996A (en) *	1985-12-23	1987-09-15	Warner-Lambert Company	Method of treating heart failure and medicaments therefor
AU618723B2 (en) *	1986-10-06	1992-01-09	University Of Virginia Alumni Patents Foundation, The	Use of an adenosine, hypoxanthine and ribose-containing solution for improved protection of the heart during surgery
US4980379A (en) *	1988-06-30	1990-12-25	The University Of Virginia	Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
US5070877A (en) *	1988-08-11	1991-12-10	Medco Research, Inc.	Novel method of myocardial imaging
US5020356A (en) *	1989-08-25	1991-06-04	Process Automation Business, Inc.	Method and apparatus for measuring characteristics of a multilayer product
US5679650A (en) *	1993-11-24	1997-10-21	Fukunaga; Atsuo F.	Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5137712A (en) *	1990-08-31	1992-08-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent supersensitivity, tolerance and extrapyramidal side effects induced by neuroleptic treatment
ES2095960T3 (es) *	1990-09-25	1997-03-01	Rhone Poulenc Rorer Int	Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
US5206222A (en) *	1991-05-22	1993-04-27	Vanderbilt University	Methods for the reduction of myocardial reperfusion injury
US5236908A (en) *	1991-06-07	1993-08-17	Gensia Pharmaceuticals, Inc.	Methods of treating injury to the central nervous system
WO1993009779A1 (en) *	1991-11-13	1993-05-27	Gensia, Inc.	Methods for increasing the sensitivity and decreasing the side effects of pharmacological stress testing for coronary artery disease

1994
- 1994-11-17 US US08/341,668 patent/US5679650A/en not_active Expired - Fee Related
- 1994-11-21 WO PCT/US1994/013412 patent/WO1995014478A1/en not_active Ceased
- 1994-11-21 AU AU12920/95A patent/AU688835B2/en not_active Ceased
- 1994-11-21 ES ES95904103T patent/ES2244962T3/es not_active Expired - Lifetime
- 1994-11-21 AT AT95904103T patent/ATE298577T1/de not_active IP Right Cessation
- 1994-11-21 DK DK95904103T patent/DK0735888T3/da active
- 1994-11-21 JP JP51516795A patent/JP3836128B2/ja not_active Expired - Fee Related
- 1994-11-21 EP EP95904103A patent/EP0735888B1/de not_active Expired - Lifetime
- 1994-11-21 DE DE69434416T patent/DE69434416T2/de not_active Expired - Fee Related
- 1994-11-21 CA CA002175828A patent/CA2175828A1/en not_active Abandoned
1997
- 1997-06-02 US US08/867,370 patent/US5942497A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2244962T3 (es)	2005-12-16
AU688835B2 (en)	1998-03-19
EP0735888A1 (de)	1996-10-09
EP0735888A4 (de)	1999-05-12
EP0735888B1 (de)	2005-06-29
US5942497A (en)	1999-08-24
DE69434416T2 (de)	2006-05-18
US5679650A (en)	1997-10-21
WO1995014478A1 (en)	1995-06-01
DE69434416D1 (de)	2005-08-04
DK0735888T3 (da)	2005-10-10
CA2175828A1 (en)	1995-06-01
JPH09505807A (ja)	1997-06-10
AU1292095A (en)	1995-06-13
JP3836128B2 (ja)	2006-10-18

Legal Events

Date	Code	Title	Description
2005-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69434416D1 (de)	2005-08-04	Präparate auf purinbasis
KR890009383A (ko)	1989-08-01	지방산 합성물
ES2036553T3 (es)	1993-06-01	Composiciones farmaceuticas que tienen actividad antineoplastica.
ES2058799T3 (es)	1994-11-01	Composiciones estabilizadas que contienen factor de crecimiento epidermico.
AR018732A1 (es)	2001-12-12	Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene.
NO943314D0 (no)	1994-09-08	Topiske aromatiske frigivingspreparater
ES2062155T3 (es)	1994-12-16	Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios.
MD1434B2 (en)	2000-03-31	1,3-Oxathiolan nucleoside analogues, pharmaceutical composition containing 1,3-oxathiolan nucleoside analogues and method of treatment of the viral infections
EA200100298A1 (ru)	2001-08-27	ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
DE69328192D1 (de)	2000-04-27	Injizierbare Arzneizubereitungen enthaltend Taxanderivate
ES8105292A1 (es)	1981-05-16	Procedimiento para la obtencion de derivado de la difenilu- rea halogenosustituidos
RU94028670A (ru)	1996-05-20	Иммунопотенциирующие агенты, способы лечения иммунодефицитных млекопитающих, а также вирусных инфекций и рака у млекопитающих
FI952248A7 (fi)	1995-05-09	Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia
MX9604271A (es)	1997-12-31	Composicion antiviral para curar heridas que contiene un piruvato, un antioxidante, una mezcla de acidos grasos y un compuesto antiviral.
AR009757A1 (es)	2000-05-03	USO DEL COMPUESTO CETRORELIX PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE BPH O CÁNCER DE PRoSTATA EN UN MAMíFERO(
LU88684I2 (fr)	1996-04-29	Complexe lipidique d'amphotericine b ainsi que leurs dérivés pharmaceutiquement acceptables (abelcet )
ES2126114T3 (es)	1999-03-16	Composiciones liquidas estables de interferon gamma.
NZ513849A (en)	2004-03-26	Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
ES8307496A1 (es)	1983-08-16	Procedimiento para la obtencion de una preparacion galenica antagonista al calcio.
KR880013574A (ko)	1988-12-21	항콕시듐증 조성물
MX9307991A (es)	1994-08-31	Analogos de insulina, procedimiento para su preparacion y formulaciones farmaceuticas que los incluyen.
ES2105923B1 (es)	1998-07-01	Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
SV1996000001A (es)	1997-02-17	Nuevas aplicaciones de dimero de lisozima
NZ214103A (en)	1989-06-28	Antimicrobial composition; synergistic mixture of maduramicin and nicarbazin
SE8403659D0 (sv)	1984-07-10	Synergistic pharmaceutical composition